U.S. Patent and Trade mark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

	SIAI	EMENT UNDER 37	<u>CFR 3.73(b)</u>
Applicant/Patent Owne	r: fx Life Sciences AG		
			ed/issue Date: March 27, 2007
Titled: HYPERICIN USE AS T-1	I AND HYPERICUM EXTR IYPE CALCIUM CHANNEL	ACT: SPECIFIC T-T TARGETED THER	YPE CALCIUM CHANNEL BLOCKER, AND THEIR APEUTICS
fx Life Sciences AG		a Swiss Corpo	ration
(Name of Assignee)		(Type of Assign	ee, e.g., corporation, partnership, university, government agency, etc.
states that it is:			
1. X the assigne	e of the entire right, title, and i	nterest in;	
an assigned (The extent)	e of less than the entire right, t (by percentage) of its owners	itle, and interest in hip interest is	%); or
3 the assigne	e of an undivided interest in th	ne entirety of (a comple	te assignment from one of the joint inventors was made)
	patent identified above, by virtu		
the United :	nent from the inventor(s) of the States Patent and Trademark ore is attached.	patent application/pate Office at Reel	ent identified above. The assignment was recorded in, Frame, or for which a
OR			
		patent application/pate	ent identified above, to the current assignee as follows:
1. From:			
	he document was recorded in leel 010625		ent and Trademark Office at or or for which a copy thereof is attached.
2. From:	CV Technologies, Inc.		To: fx Life Sciences International GmbH
T	he document was recorded in	the United States Pate	ent and Trademark Office at
F	leel 018420	Frame 0325	or for which a copy thereof is attached.
	fx Life Sciences Internation		
1	he document was recorded in	the United States Pate	ent and Trademark Office at
F	teel 022012	Frame 0925	or for which a copy thereof is attached.
Additional	documents in the chain of title	are listed on a suppler	nental sheet(s).
As required by or concurrently in	37 CFR 3.73(b)(1)(i), the docu s being, submitted for recorda	umentary evidence of the	he chain of title from the original owner to the assignee was, R 3.11.
[NOTE: A separ accordance with	rate copy (i.e., a true copy of a 37 CFR Part 3, to record the	the original assignment assignment assignment in the reco	t document(s)) must be submitted to Assignment Division in rds of the USPTO. <u>See MPEP 302.08</u>]
The undersigned (whose	se title is supplied below) is au	ithorized to act on beha	alf of the assignee.
1///	LC Eddin L	•	Johne 24, 2010
Signature			Michael D. Oberi
<u> </u>			Chief Legal Officer and Senior VP, Corporate Development
Printed or Type	ed Name		Title

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.